相关实验视频

Updated: Jun 11, 2025

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

对LBBaP与BVP在心力衰竭患者LBBBB的成本效益比率分析

Shengchan Wang¹, Siyuan Xue¹, Zhixin Jiang¹

¹Department of Cardiology, First Affiliated Hospital, Nanjing Medical University, Nanjing, China.

Pacing and clinical electrophysiology : PACE

|September 28, 2024

概括

对于心力衰竭患者,左捆支部区域节奏 (LBBaP) 比双心室节奏 (BVP) 更具成本效益. 虽然需要进一步的试验,但LBBaP提供了优异的LVEF改善和更低的住院费用.

科学领域:

心脏病学心脏病学
医疗器械医疗器械
卫生经济学卫生经济学

背景情况:

心脏再同步治疗 (CRT) 在心力衰竭 (HF) 患者的最佳初始治疗与左捆分支阻塞 (LBBB) 是有争议的.
在左捆分支区域节奏 (LBBaP) 和双心脏节奏 (BVP) 之间做出选择仍然是一个临床挑战.

研究的目的:

为了比较LBBaP与BVP的成本效益比 (CER).
评估LBBB患者接受LBBaP或BVP的心声学和临床结果.

主要方法:

观察性研究包括130名患有LBBB.的高压患者.
主要结果:心声回应,LVEF改善,住院费用和CER.
二次结果:NYHA类,NT-proBNP水平,心脏起器参数,并发症和死亡率.

主要成果:

与BVP相比,LBBaP组显著增加了LVEF (20.2%对10.5%) 和更高的心声回应率 (86.1%对57.8%).
住院费用对于LBBaP (9707.7美元) 与BVP (20,046.1美元) 相比显著降低.
而LBBaP的CER值 (112.7) 比BVP的CER值 (346.8) 更为有利.

结论:

对于患有LBBB的HF患者来说,LBBaP-CRT是一个比BVP更具成本效益的策略.
LBBaP提供了卓越的心脏功能改善和经济效益.
建议进行大型随机试验来验证这些发现.

关键词:

双心室节奏是指双心室节奏.成本效益比率是成本效益的比率.心脏衰竭是因为心脏衰竭.左捆分支机构地区节奏节奏.左捆的分支区块的分支区块.

更多相关视频

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

相关概念视频

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...